ModuleTitle@CompanyName@Symbol@Address@Phone@Industry@Sector@Region@CompanyDescription@KeyExecutives@Number_of_employees@Subsidiaries
Company Description@Biogen Inc.@BIIB@225 BINNEY STREET, CAMBRIDGE, Massachusetts, 02142, United Kingdom@7814642000@Biotechnology: Biological Products (No Diagnostic Substances)@Health Care@North America@"Biogen is a global biopharmaceutical company focused on discovering, developing
and delivering worldwide innovative therapies for people living with serious
neurological and neurodegenerative diseases as well as related therapeutic
adjacencies. Our core growth areas include multiple sclerosis (MS) and
neuroimmunology; Alzheimer's disease (AD) and dementia; neuromuscular disorders,
including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS);
movement disorders, including Parkinson's disease; and ophthalmology. We are
also focused on discovering, developing and delivering worldwide innovative
therapies in our emerging growth areas of immunology; neurocognitive disorders;
acute neurology; and pain. In addition, we commercialize biosimilars of advanced
biologics. We support our drug discovery and development efforts through the
commitment of significant resources to discovery, research and development
programs and business development opportunities.&nbsp;&nbsp;... <a href=""http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f02%2f06%2f0000875045-20-000005.html#FIS_BUSINESS"" target=""_blank"">More</a> ...&nbsp;&nbsp;
"@[('Alfred W. Sandrock', 'Chief Medical Officer & EVP-Research & Development'), ('Jeffrey D. Capello', 'Chief Financial Officer & Executive Vice President'), ('Mark Hernon', 'Chief Information Officer & Senior Vice President'), ('Michel Vounatsos', 'Chief Executive Officer & Director')]@['7,300']@['NO INFO']
